New technology represents next-generation tool for detecting substandard and counterfeit medicines

A new platform for detecting substandard and counterfeit medicines using microfluidics has been recognized with a grant from Saving Lives at Birth's "Grand Challenge through Development." Dubbed PharmaCheck, the technology is a portable, field-based tool for assessing the quality of medicines in developing countries with increased accuracy, sensitivity and reliability.

Through the Challenge, the U.S. Agency for International Development (USAID), Bill & Melinda Gates Foundation, Grand Challenges Canada and the U.K. Department for International Development sought groundbreaking prevention and treatment approaches for pregnant women and newborns in poor, hard-to-reach communities in . Substandard and counterfeit medicines for diseases including malaria, tuberculosis and HIV/AIDS pose a dire public health threat to patients in developing countries, in particular children and pregnant women. Such medicines can exacerbate the course of these diseases, even leading to death, as well as contribute to the growth of drug-resistant disease parasites—threatening the viability of treatments for patients worldwide.

Developed by Boston University in collaboration with the Promoting the Quality of Medicines (PQM) program, which is supported by USAID and implemented by the U.S. Pharmacopeial Convention (USP), PharmaCheck has reached the proof of concept stage—demonstrating a quantitation linear relationship for analysis of an antimalarial medicine of interest on a microfluidic chip. The technology addresses shortcomings of current field-based, portable quality control laboratories currently in use throughout the developing world—including the inability to precisely and accurately measure the percentage of the active pharmaceutical ingredient or other important quality attributes of medicines. These are key to determining whether a medicine is of poor quality or not. Furthermore, the technology is expected to greatly reduce the need for confirmation of field-tested results at fully equipped quality control laboratories.

"This technology promises to be groundbreaking in the fight against substandard and ," said Mr. Anthony Boni, Pharmaceutical Management Specialist for USAID's Global Health Bureau, Office of Health, Infectious Diseases and Nutrition/Health Systems Division. "Inexpensive, easy-to-use and effective, we expect that PharmaCheck will represent a paradigm shift in combating the scourge of poor-quality medicines. One of the most exciting elements is the ability to potentially deploy this technology at point-of-use, with an ultimate vision of healthcare facilities, clinics and hospitals using the technology to verify the quality of the medicines they receive."

"This technology is an important breakthrough as we strive to help ensure the quality, safety and efficacy of medicines essential to treating patients suffering from malaria, tuberculosis and HIV/AIDS in developing countries around the world," said Dr. Patrick Lukulay, Vice President of Global Health Impact Programs for USP and Director of the PQM Program. "This will be a very powerful tool with broad application and impact. We are very pleased to be partnering with Boston University in advancing this technology."

With this new grant, Boston University, led by Dr. Muhammad Zaman, will be able to accelerate development of PharmaCheck and the deployment of a finished product.

add to favorites email to friend print save as pdf

Related Stories

Fake malaria drugs threaten crisis in Africa

Jan 17, 2012

(Medical Xpress) -- The emergence of fake and poor quality anti-malarial drugs could dash hopes of controlling malaria in Africa, warn experts writing in the Malaria Journal. Millions of lives could be put ...

More AIDS patients may get cheaper drugs

Jul 12, 2011

(AP) -- Gilead Sciences Inc. will allow some of its AIDS drugs to be made by generic manufacturers, potentially increasing their availability in poor countries, particularly in Africa, officials said Tuesday.

Recommended for you

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

EU regulator: Morning-after pill OK for all women

Jul 24, 2014

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

Physicians warned about counterfeit medical devices

Jul 24, 2014

(HealthDay)—Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices, according to a letter to the editor published online July 20 in Lasers in ...

User comments